Allspring Global Investments
PLX icon

Allspring Global Investments’s Protalix BioTherapeutics PLX Stock Holding History

Allspring Global Investments’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-137,906
Closed -$229K – 2621
2023
Q3 		$229K Buy
+137,906
New +$248K ﹤0.01% 1725

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Allspring Global Investments's PLX Position: Q4 2023 in Review

Allspring Global Investments sold out of Protalix BioTherapeutics (PLX) in Q4 2023, closing a stake of 137,906 shares — an estimated $229K sold.

Allspring Global Investments first reported a position in PLX in Q3 2023 and held it in 1 quarter. The position peaked at $229K in Q3 2023. 66 funds tracked by Wall St. Rank hold PLX as of Q4 2023.

  • Allspring Global Investments reported no remaining Protalix BioTherapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 137,906 Protalix BioTherapeutics shares in Q4 2023, an estimated $229K.
  • Allspring Global Investments first reported a position in Protalix BioTherapeutics in Q3 2023 and held it in 1 quarter.
  • Allspring Global Investments's Protalix BioTherapeutics position peaked at $229K in Q3 2023.
  • 66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.